본문 바로가기

Efficacy and Safety of Ursodeoxycholic Acid for the Prevention of Gallstone Formation After Gastrectomy in Patients With Gastric Cancer The PEGASUS-D Randomized Clinical Trial

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q1
저널
JAMA SURGERY155(8) · pp.703 · 2020
피인용
Web of Science 42Scopus 36
FWCI (Scopus)
0
JCR IF
JCR 2019 13.625
ISSN
2168-6254

저자

  1. Lee, Sang Hyub제1저자Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea
  2. Jang, Dong KeeDepartment of Internal Medicine, Dongguk University Ilsan Hospital, Goyang, Republic of Korea
  3. Yoo, Moon-WonDepartment of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
  4. 황순휘Department of Surgery, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea
  5. Ryu, Seong-YeobDepartment of Surgery, Chonnam National University Hwasun Hospital, Hwasun, Republic of Korea
  6. Kwon, Oh KyoungDepartment of Surgery, Kyoungpook National University Chilgok Hospital, Daegu, Republic of Korea
  7. Hur, HoonDepartment of Surgery, Ajou University Hospital, Suwon, Republic of Korea
  8. Man Yoon, HongCenter for Gastric Cancer, National Cancer Center, Goyang, Republic of Korea
  9. Eom, Bang WoolCenter for Gastric Cancer, National Cancer Center, Goyang, Republic of Korea
  10. Ahn, Hye SeongDepartment of Surgery, Boramae Medical Center, Seoul, Republic of Korea
  11. Son, TaeilDepartment of Surgery, Yonsei University Severance Hospital, Seoul, Republic of Korea
  12. Song, Kyo YoungDepartment of Surgery, Catholic University of Seoul St Mary's Hospital, Seoul, Republic of Korea
  13. Lee, Han HongDepartment of Surgery, Catholic University of Seoul St Mary's Hospital, Seoul, Republic of Korea
  14. Choi, Min-GewDepartment of Surgery, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
  15. An, Ji YeongDepartment of Surgery, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
  16. Lee, Sang-IlDepartment of Surgery, Chungnam National University Hospital, Daejeon, Republic of Korea
  17. Lee, Kyung HoDepartment of Radiology, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea
  18. Ahn, SoyeonMedical Research Collaborating Center, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea
  19. Park, Young SukDepartment of Surgery, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea
  20. Park, Do Joong교신저자Department of Surgery, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea

초록

IMPORTANCE The incidence of gallstones has been reported to increase after gastrectomy. However, few studies have been conducted on the prevention of gallstone formation in patients who have undergone gastrectomy. OBJECTIVE To evaluate the efficacy and safety of ursodeoxycholic acid (UDCA) in preventing gallstone formation after gastrectomy in patients with gastric cancer. DESIGN, SETTING, AND PARTICIPANTS The PEGASUS-D study (Efficacy and Safety of DWJ1319 in the Prevention of Gallstone Formation after Gastrectomy in Patient with Gastric Cancer: A Multicenter, Randomized, Double-blind, Placebo-controlled Study) was a randomized, double-blind, placebo-controlled clinical trial conducted at 12 institutions in the Republic of Korea. Adults (aged >= 19 years) with a diagnosis of gastric cancer who underwent total, distal, or proximal gastrectomy were enrolled between May 26, 2015, and January 9, 2017; follow-up ended January 8, 2018. Efficacy was evaluated by both the full analysis set, based on the intention-to-treat principle, and the per-protocol set; full analysis set findings were interpreted as the main results. INTERVENTIONS Eligible participants were randomly assigned to receive 300 mg of UDCA, 600 mg of UDCA, or placebo at a ratio of 1:1:1. Ursodeoxycholic acid and placebo were administered daily for 52 weeks. MAIN OUTCOMES AND MEASURES Gallstone formation was assessed with abdominal ultrasonography every 3 months for 12 months. Randomization and allocation to trial groups were carried out by an interactive web-response system. The primary end point was the proportion of patients developing gallstones within 12 months after gastrectomy. RESULTS A total of 521 patients (175 received 300 mg of UDCA, 178 received 600 mg of UDCA, and 168 received placebo) were randomized. The full analysis set included 465 patients (311 men; median age, 56.0 years [interquartile range, 48.0-64.0 years]), with 151 patients in the 300-mg group, 164 patients in the 600-mg group, and 150 patients in the placebo group. The proportion of patients developing gallstones within 12 months after gastrectomy was 8 of 151 (5.3%) in the 300-mg group, 7 of 164 (4.3%) in the 600-mg group, and 25 of 150 (16.7%) in the placebo group. Compared with the placebo group, odds ratios for gallstone formation were 0.27 (95% CI, 0.12-0.62; P = .002) in the 300-mg group and 0.20 (95% CI, 0.08-0.50; P < .001) in the 600-mg group. No significant adverse drug reactions were detected among the enrolled patients. CONCLUSIONS AND RELEVANCE Administration of UDCA for 12 months significantly reduced the incidence of gallstones after gastrectomy for gastric cancer. These findings suggest that UDCA administration prevents gallstone formation after gastrectomy in patients with gastric cancer.

키워드

CHOLESTATIC LIVER-DISEASELAPAROSCOPIC CHOLECYSTECTOMYDOUBLE-BLINDWEIGHT-LOSSCONCOMITANT CHOLECYSTECTOMYGALLBLADDER STONESBARIATRIC SURGERYRISK-FACTORSCHOLELITHIASISCONTRACTILITY

식별자

Scopus EID
2-s2.0-85086842946
WoS UID
000564292600007